These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 21526201)
1. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. Chen Z; Zhu Y; Ren Y; Tong Y; Hua X; Zhu F; Huang L; Liu Y; Luo Y; Lu W; Zhao P; Qi Z PLoS One; 2011 Apr; 6(4):e18933. PubMed ID: 21526201 [TBL] [Abstract][Full Text] [Related]
2. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. Tong Y; Zhu Y; Xia X; Liu Y; Feng Y; Hua X; Chen Z; Ding H; Gao L; Wang Y; Feitelson MA; Zhao P; Qi ZT J Virol; 2011 Mar; 85(6):2793-802. PubMed ID: 21177818 [TBL] [Abstract][Full Text] [Related]
3. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607 [TBL] [Abstract][Full Text] [Related]
4. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Rothwangl KB; Manicassamy B; Uprichard SL; Rong L Virol J; 2008 Mar; 5():46. PubMed ID: 18355410 [TBL] [Abstract][Full Text] [Related]
5. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. Mongini PK; Jackson AE; Tolani S; Fattah RJ; Inman JK J Immunol; 2003 Nov; 171(10):5244-54. PubMed ID: 14607925 [TBL] [Abstract][Full Text] [Related]
6. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. Grove J; Nielsen S; Zhong J; Bassendine MF; Drummer HE; Balfe P; McKeating JA J Virol; 2008 Dec; 82(24):12020-9. PubMed ID: 18829747 [TBL] [Abstract][Full Text] [Related]
7. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001 [TBL] [Abstract][Full Text] [Related]
8. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Rosa D; Saletti G; De Gregorio E; Zorat F; Comar C; D'Oro U; Nuti S; Houghton M; Barnaba V; Pozzato G; Abrignani S Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18544-9. PubMed ID: 16339892 [TBL] [Abstract][Full Text] [Related]
9. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. Tseng CT; Klimpel GR J Exp Med; 2002 Jan; 195(1):43-9. PubMed ID: 11781364 [TBL] [Abstract][Full Text] [Related]
10. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. Mazzocca A; Sciammetta SC; Carloni V; Cosmi L; Annunziato F; Harada T; Abrignani S; Pinzani M J Biol Chem; 2005 Mar; 280(12):11329-39. PubMed ID: 15611113 [TBL] [Abstract][Full Text] [Related]
11. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. Meola A; Sbardellati A; Bruni Ercole B; Cerretani M; Pezzanera M; Ceccacci A; Vitelli A; Levy S; Nicosia A; Traboni C; McKeating J; Scarselli E J Virol; 2000 Jul; 74(13):5933-8. PubMed ID: 10846074 [TBL] [Abstract][Full Text] [Related]
12. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. Owsianka AM; Timms JM; Tarr AW; Brown RJ; Hickling TP; Szwejk A; Bienkowska-Szewczyk K; Thomson BJ; Patel AH; Ball JK J Virol; 2006 Sep; 80(17):8695-704. PubMed ID: 16912317 [TBL] [Abstract][Full Text] [Related]
13. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994 [TBL] [Abstract][Full Text] [Related]
14. Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells. Park GB; Kim D; Park SJ; Lee HK; Kim JH; Kim YS; Park SG; Choi IH; Yoon SH; Lee YJ; Paeng S; Hur DY Int J Mol Med; 2015 Dec; 36(6):1464-78. PubMed ID: 26498453 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus entry: potential receptors and their biological functions. Cocquerel L; Voisset C; Dubuisson J J Gen Virol; 2006 May; 87(Pt 5):1075-1084. PubMed ID: 16603507 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein. Heo TH; Lee SM; Bartosch B; Cosset FL; Kang CY Virus Res; 2006 Oct; 121(1):58-64. PubMed ID: 16725222 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838 [TBL] [Abstract][Full Text] [Related]
18. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. Wünschmann S; Medh JD; Klinzmann D; Schmidt WN; Stapleton JT J Virol; 2000 Nov; 74(21):10055-62. PubMed ID: 11024134 [TBL] [Abstract][Full Text] [Related]
19. Diverse CD81 proteins support hepatitis C virus infection. Flint M; von Hahn T; Zhang J; Farquhar M; Jones CT; Balfe P; Rice CM; McKeating JA J Virol; 2006 Nov; 80(22):11331-42. PubMed ID: 16943299 [TBL] [Abstract][Full Text] [Related]
20. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]